Literature DB >> 32253141

Reproducibility of LI-RADS treatment response algorithm for hepatocellular carcinoma after locoregional therapy.

A A K Abdel Razek1, L G El-Serougy2, G A Saleh2, W Shabana3, R Abd El-Wahab2.   

Abstract

PURPOSE: To determine inter-reader agreement in categorizing hepatocellular carcinoma (HCC) treated with locoregional therapy using the Liver Imaging Reporting and Data System (LI-RADS) treatment response (LR-TR) algorithm.
MATERIALS AND METHODS: A total of 93 patients with a total of 112 HCC nodules that were treated using thermal ablation or transarterial chemoembolization were prospectively included. There were 79 men and 14 women with a mean age of 55±2.6 (SD)years (range: 48-63years). All patients underwent magnetic resonance imaging (MRI) examination of the liver and MR images were analyzed by two independent observers. Treated HCC nodules were categorized into four groups according to LR-TR scoring system including: (i) LR-TR non-evaluable (treated, response not evaluable); (ii) LR-TR nonviable (treated, probably or definitively not viable); (iii) LR-TR equivocal (treated, equivocally viable) and (iv) LR-TR viable (treated, probably or definitively viable). The inter-observer agreement in LR-TR categorization was assessed using the kappa statistics.
RESULTS: There was excellent inter-observer agreement between the two reviewers for overall treated HCC according to LR-TR algorithm (kappa=0.938; 95% CI: 0.89-1.00; P=0.001) with 97.31% agreement. The LR-TR categories by both reviewers were non-viable (77/112; 69.6% and 76/112; 67.9%), viable (30/112; 26.8% and 32/112; 27.7%) and equivocal (5/112; 4.4% and 4/112; 3.6%). There was excellent inter-observer agreement for LR-TR nonviable (kappa=0.938; 95% CI: 0.87-1.0; P=0.001) with 97.3% agreement, LR-TR viable (kappa=0.955; 95% CI: 0.89-1.00; P=0.001) with 98.2% agreement and good inter-observer agreement for LR-TR equivocal (kappa=0.700; 95% CI: 0.28-1.0; P=0.001) with 97.3% agreement.
CONCLUSION: LR-TR algorithm conveys high degrees of inter-observer agreement for the evaluation of treatment response of HCC after thermal ablation and transarterial chemoembolization.
Copyright © 2020 Société française de radiologie. Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Chemoembolization; Hepatocellular carcinoma; LI-RADS treatment response; MR imaging; Observer variation; Response; Therapeutic

Mesh:

Substances:

Year:  2020        PMID: 32253141     DOI: 10.1016/j.diii.2020.03.008

Source DB:  PubMed          Journal:  Diagn Interv Imaging        ISSN: 2211-5684            Impact factor:   4.026


  8 in total

Review 1.  Artificial intelligence in assessment of hepatocellular carcinoma treatment response.

Authors:  Bradley Spieler; Carl Sabottke; Ahmed W Moawad; Ahmed M Gabr; Mustafa R Bashir; Richard Kinh Gian Do; Vahid Yaghmai; Radu Rozenberg; Marielia Gerena; Joseph Yacoub; Khaled M Elsayes
Journal:  Abdom Radiol (NY)       Date:  2021-03-31

2.  Utility of diffusion tensor imaging in differentiating benign from malignant hepatic focal lesions.

Authors:  Gehad A Saleh; Ali H Elmokadem; Ahmed Abdel Razek; Ahmed El-Morsy; Omar Hamdy; Elshimaa S Eleraky; Marwa Saleh
Journal:  Eur Radiol       Date:  2022-08-18       Impact factor: 7.034

3.  Clinical outcomes of patients with a high alpha-fetoprotein level but without evident recurrence on CT or MRI in surveillance after curative-intent treatment for hepatocellular carcinoma.

Authors:  Jihyuk Lee; Ijin Joo; Dong Ho Lee; Sun Kyung Jeon; Jeong Min Lee
Journal:  Abdom Radiol (NY)       Date:  2020-08-18

Review 4.  Interreader Reliability of Liver Imaging Reporting and Data System Treatment Response: A Systematic Review and Meta-Analysis.

Authors:  Dong Wook Kim; Sang Hyun Choi; Ji Sung Lee; So Yeon Kim; So Jung Lee; Jae Ho Byun
Journal:  Diagnostics (Basel)       Date:  2021-02-04

5.  Efficacy of the association liver partition and portal vein ligation for staged hepatectomy for the treatment of solitary huge hepatocellular carcinoma: a retrospective single-center study.

Authors:  Zhenfeng Deng; Zongrui Jin; Yonghui Qin; Mingqi Wei; Jilong Wang; Tingting Lu; Ling Zhang; Jingjing Zeng; Li Bao; Ya Guo; Minhao Peng; Banghao Xu; Zhang Wen
Journal:  World J Surg Oncol       Date:  2021-03-30       Impact factor: 2.754

6.  Performance of initial LI-RADS 2018 treatment response in predicting survival of patients with hepatocellular carcinoma following TACE: a retrospective, single-center cohort study.

Authors:  Krzysztof Bartnik; Joanna Podgórska; Grzegorz Rosiak; Krzysztof Korzeniowski; Jakub Giziński; Michał Sajdek; Tadeusz Wróblewski; Krzysztof Zieniewicz; Paweł Nyckowski; Olgierd Rowiński
Journal:  J Cancer Res Clin Oncol       Date:  2021-03-28       Impact factor: 4.553

7.  The value of the apparent diffusion coefficient value in the Liver Imaging Reporting and Data System (LI-RADS) version 2018.

Authors:  Gehad Ahmad Saleh; Ahmed Abdel Khalek Abdel Razek; Lamiaa Galal El-Serougy; Walaa Shabana; Rihame Abd El-Wahab
Journal:  Pol J Radiol       Date:  2022-01-17

8.  Inter-observer agreement using the LI-RADS version 2018 CT treatment response algorithm in patients with hepatocellular carcinoma treated with conventional transarterial chemoembolization.

Authors:  Krzysztof Bartnik; Joanna Podgórska; Grzegorz Rosiak; Krzysztof Korzeniowski; Olgierd Rowiński
Journal:  Abdom Radiol (NY)       Date:  2021-09-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.